{
    "clinical_study": {
        "@rank": "3245", 
        "arm_group": [
            {
                "arm_group_label": "Patient: LGT209 0.3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Patient: LGT209 1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "1 mg/kg LGT209 intravenous administration in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Patient: LGT209 3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "3 mg/kg LGT209 intravenous administration in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Patient: LGT209 10 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg LGT209 intravenous administration in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Patient: LGT209 20 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "20 mg/kg LGT209 intravenous administration in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: LGT209 0.3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "0.3 mg/kg LGT209 intravenous administration in healthy volunteers"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: LGT209 1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "1 mg/kg LGT209 intravenous administration in healthy volunteers"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: LGT209 3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "3 mg/kg LGT209 intravenous administration in healthy volunteers"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: LGT209 10 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg LGT209 intravenous administration in healthy volunteers"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: 20 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "20 mg/kg LGT209 intravenous administration in healthy volunteers"
            }, 
            {
                "arm_group_label": "Patient: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching intravenous placebo in patients on stable doses of statins"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching intravenous placebo in healthy volunteers"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to measure the effects of LGT209 when given intravenously to patients\n      with high cholesterol who are on stable doses of statin medications, and to healthy subjects\n      with elevated cholesterol"
        }, 
        "brief_title": "Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good\n             health but with high cholesterol\n\n          -  Statin patients: Male and female patients 18 to 70 years of age, with high\n             cholesterol on stable statin therapy for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Healthy volunteers: History of hypersensitivity to any of the study drugs or to drugs\n             of similar chemical classes\n\n          -  Women of child-bearing potential unless using highly effective methods of\n             contraception\n\n          -  Statin patients: Use of any prescription drugs for lipid lowering other than HMG CO-A\n             reductase inhibitors (statins); use of two concurrent antihypertensive medications is\n             allowed, provided stable dosing has been achieved for the prior 3 months\n\n          -  Women of child-bearing potential unless using highly effective methods of\n             contraception\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979601", 
            "org_study_id": "CLGT209X2101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Patient: LGT209 0.3 mg/kg", 
                    "Patient: LGT209 1 mg/kg", 
                    "Patient: LGT209 3 mg/kg", 
                    "Patient: LGT209 10 mg/kg", 
                    "Patient: LGT209 20 mg/kg", 
                    "Healthy Volunteers: LGT209 0.3 mg/kg", 
                    "Healthy Volunteers: LGT209 1 mg/kg", 
                    "Healthy Volunteers: LGT209 3 mg/kg", 
                    "Healthy Volunteers: LGT209 10 mg/kg", 
                    "Healthy Volunteers: 20 mg/kg"
                ], 
                "description": "150 mg lyophilized powder in glass vial", 
                "intervention_name": "LGT209", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Patient: Placebo", 
                    "Healthy Volunteers: Placebo"
                ], 
                "description": "Placebo comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "hypercholesterolemia,", 
            "LGT209,", 
            "PCSK9,", 
            "LDL-C"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami Gardens", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58104"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "12", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia on Stable Doses of Statin Medications", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "from Screening until Day 141"
            }, 
            {
                "description": "Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)", 
                "measure": "Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in healthy volunteers", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "description": "Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)", 
                "measure": "Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in healthy volunteers", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: : Area under the serum concentration-time curve from time zero to infinity (AUC0-inf) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2); 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: observed maximum serum concentrations (Cmax) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (T1/2) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Number of healthy volunteers with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "from Screening until Day 141"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics of intravenous LGT209 in relationship to concentrations of PCSK9 and LDL-C in patients and healthy volunteers", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "description": "Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)", 
                "measure": "Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "description": "Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)", 
                "measure": "Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "description": "In AUC 0-t, t is a defined as time point after administration of LGT209 in patients and healthy volunteers following intravenous administration", 
                "measure": "Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to time 't' (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Dose-normalized area under the serum concentration-time curve (AUC/D) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Dose-normalized maximum serum concentrations (Cmax/D) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 ( 1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Volume of distribution during the terminal elimination phase (Vz) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Volume of distribution at steady state (Vss) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: Mean residence time (MRT) of LGT209 in patients and healthy volunteers following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }, 
            {
                "measure": "Pharmacokinetics of LGT209: the systemic (or total body) clearance from serum following intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}